Omada Health’s GLP-1 Behavior Change Companion Programs Help Drive Lasting, Long-Term Weight Loss

Core Insights - Omada Health's program, when paired with GLP-1 medications, demonstrates significant weight loss and persistence compared to real-world evidence, highlighting its value for employers in managing weight loss medication complexities [1][2][3] Program Outcomes - Members who remained in the program for 12 months experienced an average weight loss of 18.4%, significantly higher than the 11.9% weight loss reported in real-world evidence [2] - Omada members achieved 47% greater average weight loss on semaglutide and 37% greater weight loss on tirzepatide compared to published real-world evidence [2] - Overall, members in the program, regardless of medication persistence, achieved an average weight loss of 16.3%, nearly double that observed in real-world analyses [2] Medication Persistence - 67% of Omada members maintained their GLP-1 medication for one year, surpassing the 47-49% persistence rate found in comparable studies [4] - Members who discontinued medication before one year had an average weight loss of 13.1%, compared to 6.8% among similar patients in other studies [4] Support and Care Model - Omada's Enhanced GLP-1 Care Track provides comprehensive support, helping members navigate their weight loss journey and manage medication side effects [5] - The program combines specialized care team support with tailored content to optimize the medication experience for members [5] Real-World Data and Research - Omada emphasizes the importance of real-world data, tracking outcomes in real-time to ensure the effectiveness of its program as medications and access evolve [6] - The study is part of the Omada Insights Lab ANSWERS Initiative, which focuses on analyzing real-world evidence related to weight medication [6] Company Overview - Omada Health is a virtual healthcare provider addressing cardiometabolic conditions and supporting members taking GLP-1 and other anti-obesity medications [8] - The company has served over one million members and has published 30 peer-reviewed studies demonstrating its clinical and economic results [9]